- 01 Oct `26Ruxolitinib cream for children ages 6 to 11Recruiting nowThis Phase 3 study is evaluating the safety and efficacy of ruxolitinib cream in children ages 6–11 with nonsegmental vitiligo.During the first 24 weeks, participants receive one of two strengths of ruxolitinib cream or a matching cream (called "v...
Location: 79 listed sites: Argentina (8); Austria (2); Belgium (4); Bulgaria (7); Denmark (2); France (10); Germany (8); Hungary (4); Italy (9); Netherlands (1); Poland (9); Portugal (3); Spain (6); United Kingdom (6) - 01 Oct `26This Phase 3 study is evaluating the safety and efficacy of ruxolitinib 1.5% cream in children ages 2–11 with nonsegmental vitiligo.During the first 24 weeks, participants receive ruxolitinib cream or a matching cream (called "vehicle") with no ac...
Location: 88 listed sites: Canada (19); United States (69) - 30 Sep `26Assessment of Vitiligo Lesions Using Polarized Dermoscopy, Sub-Ultraviolet Reflectance Dermoscopy, and Ultraviolet DermoscopyRecruiting nowThe goal of this observational study is to learn how different close-up skin imaging methods show vitiligo spots in adults with vitiligo. The study will look at skin changes that may be related to whether a vitiligo spot is active, stable, or gain...
Location: University of Health Sciences Istanbul Training and Research Hospital, Istanbul, Turkey (Türkiye) - 04 Sep `26Zasocitinib tablets for nonsegmental vitiligoRecruiting nowTakeda plans to enroll about 200 participants. The study drug is an experimental oral or topical immune-modulating medicine designed to reduce inflammatory signaling. Researchers hope it will slow melanocyte damage and help skin regain color. Poss...
Location: 68 listed sites: Canada (8); China (5); France (6); Italy (5); Japan (5); Mexico (4); Poland (8); Spain (6); United States (21) - 04 Sep `26Roflumilast Foam for Facial VitiligoRecruiting nowAn open-label single center, proof of concept study evaluating the efficacy of Roflumilast foam 0.3% in pediatric subjects with Non-Segmental Vitiligo (NSV)Phase: Phase 2.What is being studied: Drug: Roflumilast topical 0.3% foam.Who can take part...
Location: Derm Texas, Dallas, Texas, 75235, United States - 21 Aug `26Long-term safety registry for vitiligo treatmentsRecruiting nowCorEvitas plans to enroll about 2,500 participants. This is an observational study, so researchers will not assign an experimental treatment. Researchers are tracking the long-term safety and real-world results of vitiligo treatments in adults and...
Location: CorEvitas, LLC, Waltham, Massachusetts, United States (Recruiting) - 04 Aug `26MH004 ointment for nonsegmental vitiligoRecruiting nowMinghui Pharmaceutical (Hangzhou) Ltd plans to enroll about 405 participants. The experimental topical medicine is designed to reduce inflammation in vitiligo-affected skin. Researchers hope it will protect melanocytes and improve repigmentation. ...
Location: Peking University People's Hospital, Beijing, Beijing Municipality, China (Recruiting) - 20 Jun `26Ruxolitinib Cream Combined With Corticosteroids for Progressive Non-Segmental Vitiligo: A Multicenter Real-World StudyRecruiting nowThis study is a prospective, multicenter, real-world observational study to assess the clinical efficacy and safety of topical 1.5% Ruxolitinib phosphate cream used in combination with systemic corticosteroids in a real-world clinical setting. The...
Location: Shenzhen Hospital of Southern Medical University, Shenzhen, Guangdong, China - 11 Jun `26D-2570 tablets for nonsegmental vitiligoRecruiting nowInventisBio Co., Ltd plans to enroll about 160 participants. The study drug is an experimental oral or topical immune-modulating medicine designed to reduce inflammatory signaling. Researchers hope it will slow melanocyte damage and help skin rega...
Location: Huashan Hospital, Fudan University, Shanghai, Shanghai Municipality, China (Recruiting) - 01 Jun `26Aswan University plans to enroll about 40 participants. Fluorouracil is applied after needling or laser treatment to encourage pigment cells to move into pale skin. Researchers hope the combination will improve repigmentation in stable vitiligo. F...
Location: Aswan University Hospital, Aswān, Egypt (Recruiting) - 18 Apr `26IBI3013 or baricitinib for nonsegmental vitiligoRecruiting nowInnovent Biologics (Suzhou) Co. Ltd. plans to enroll about 160 participants. The experimental antibody blocks IL-15, an immune signal that helps pigment-destroying T cells survive. Researchers hope it will reduce the immune attack on melanocytes a...
Location: Huashan Hospital, Fudan University, Shanghai, Shanghai Municipality, China (Recruiting) - 14 Apr `26LY4005130 antibody treatment for nonsegmental vitiligoRecruiting nowEli Lilly and Company plans to enroll about 66 participants. LY4005130 is an experimental antibody that neutralizes XCL1 and XCL2 signals linked to harmful CD8 T cells. It is designed to reduce the immune attack on melanocytes and encourage repigm...
Location: 35 listed sites: Belgium (3); Canada (6); China (4); Poland (4); United States (18) - 29 Mar `26GIA632 antibody treatment for nonsegmental vitiligoRecruiting nowNovartis Pharmaceuticals plans to enroll about 210 participants. The experimental antibody blocks IL-15, an immune signal that helps pigment-destroying T cells survive. Researchers hope it will reduce the immune attack on melanocytes and allow ski...
Location: 72 listed sites: Argentina (1); Australia (3); Canada (6); China (4); France (7); Germany (8); India (5); Italy (4); Japan (4); Netherlands (2); Spain (7); United States (21) - 12 Mar `26Ritlecitinib with or without UVB light therapyRecruiting nowCentre Hospitalier Universitaire de Nice plans to enroll about 56 participants. Ritlecitinib is an oral immune-modulating drug that blocks JAK3 and TEC-family signaling. Researchers hope it will reduce the immune attack on melanocytes and support ...
Location: 5 listed sites: France (5) - 02 Feb `26Melanotan II with light therapy for vitiligoRecruiting nowHudson Biotech plans to enroll about 60 participants. Melanotan II is an unapproved synthetic hormone-like compound that stimulates melanin production. Combined with UVB light, it may increase skin pigmentation. Possible effects include nausea, fl...
Location: Peking University Shenzhen Hospital, Shenzhen, Guangdong, China (Recruiting) - 31 Dec `25Factors that affect response to ruxolitinib creamRecruiting nowPeking University Third Hospital plans to enroll about 170 participants. This is an observational study, so researchers will not assign an experimental treatment. Researchers are studying which patient and treatment factors affect how well ruxolit...
Location: Peking University Third Hospital, Beijing, China (Recruiting) - 30 Dec `25EI-001 antibody treatment for nonsegmental vitiligoRecruiting nowElixiron Immunotherapeutics (Hong Kong) Ltd. plans to enroll about 45 participants. EI-001 is an experimental antibody that blocks interferon-gamma, an inflammatory signal involved in melanocyte damage. Researchers hope it will protect pigment-pro...
Location: 5 listed sites: Taiwan (1); United States (4) - 10 Dec `25Targeted UVB laser treatment for vitiligoRecruiting nowSzeged University plans to enroll about 50 participants. The procedure makes controlled tiny injuries in the skin, sometimes to improve delivery of a medicine or add targeted UVB light. This may stimulate healing and help pigment cells move into o...
Location: University of Szeged, Albert Szent-Györgyi Clinical Centre, Department of Dermatology and Allergology, Szeged, Csongrád-Csanád Vármegye, Hungary (Recruiting) - 05 Dec `25SHR0302 tablets and gel for nonsegmental vitiligoRecruiting nowJiangsu HengRui Medicine Co., Ltd. plans to enroll about 176 participants. The study drug is an experimental oral or topical immune-modulating medicine designed to reduce inflammatory signaling. Researchers hope it will slow melanocyte damage and ...
Location: Dermatology Hospital affiliated to Shandong First Medical University, Jinan, Shandong, China (Recruiting) - 11 Nov `25QY201 tablets for nonsegmental vitiligoRecruiting nowE-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. plans to enroll about 200 participants. The study drug is an experimental oral or topical immune-modulating medicine designed to reduce inflammatory signaling. Researchers hope it will slow melanoc...
Location: The First Hospital of China Medical University, Shenyang, Liaoning, China (Recruiting) - 10 Nov `25Betamethasone Phonophoresis For VitiligoRecruiting nowVitiligo is a skin disorder that results in the formation of depigmented patches or hypopigmented macules due to selective destruction or reduction of melanocytes the cells that produce pigment in our skin. Vitiligo affects 0.1-2% of the World's p...
Location: Cairo University Hospital, Cairo, Egypt - 31 Oct `25VC005 tablets for nonsegmental vitiligoRecruiting nowJiangsu vcare pharmaceutical technology co., LTD plans to enroll about 120 participants. The study drug is an experimental oral or topical immune-modulating medicine designed to reduce inflammatory signaling. Researchers hope it will slow melanocy...
Location: The Peking University People's Hospital, Beijing, Beijng, China (Recruiting) - 02 Sep `25Daily burden of vitiligo and other skin diseasesRecruiting nowAbbVie plans to enroll about 2,795 participants. This is an observational study, so researchers will not assign an experimental treatment. Researchers are measuring how vitiligo and two other skin conditions affect symptoms, daily life, work, and ...
Location: 116 listed sites: Argentina (5); Canada (9); Colombia (2); Czechia (3); Estonia (2); France (22); Germany (21); Greece (6); Italy (3); Japan (4); Latvia (1); Puerto Rico (3); Romania (7); South Korea (2); Spain (6); Switzerland (10); Taiwan (2); United Kingdom (8) - 08 Aug `25Effectiveness of Micro-needling With 5 Fluorouracil Versus Potent Topical Steroids in the Treatment of Limited VitiligoRecruiting nowThe goal of this clinical trial is to learn how well 5 fluorouracil (5FU) with micro-needling works to treat limited vitiligo as compared to strong steroid applied on skin. It will also learn about the safety of both these treatments. The main que...
Location: CMH Bahawalpur, Chak Four Hundred Fifty-four, Pakistan - 25 Jul `25CGB-600 gel for facial vitiligoRecruiting nowCAGE Bio Inc. plans to enroll about 36 participants. The experimental topical medicine is designed to reduce inflammation in vitiligo-affected skin. Researchers hope it will protect melanocytes and improve repigmentation. Possible effects may incl...
Location: Ankara T.C. Ministry of Health, Ankara, Turkey, Turkey (Türkiye) (Recruiting); Istanbul Universitesi faculty of Medicine, Istanbul, Turkey, Turkey (Türkiye) (Recruiting)
Seeking a Clinical Trial in Vitiligo
Clinical trials help researchers learn whether new ways to diagnose, manage, or treat vitiligo are safe and effective. They may test a medicine, light therapy, a procedure, or a combination of treatments. Some studies simply follow people over time — no experimental treatment involved.
VRF lists studies from public registries. We do not screen or recommend joining. Some sponsors contract with us for study-awareness support; those placements are disclosed when they go live. Status and sites change. Confirm them on the official record and with the research site.
If this is unfamiliar territory, start with the FAQ.
Find vitiligo studies nearby
Vitiligo Studies Recruiting Now
70 trials in total
FAQOther Questions
- Which diseases most commonly accompany vitiligo?
Vitiligo is rarely an isolated event. Because it involves an overactive immune system, it often coexists with other autoimmune disorders. According to extensive 10-year clinical...
- Who is prone to vitiligo?
Vitiligo can affect anyone, regardless of gender, age, or race. Vitiligo prevalence is between 0.76% and 1.11% of the U.S. population, including around 40% of those with the con...
- Is vitiligo contagious?
Vitiligo is not contagious. This means it cannot be spread from person to person through physical contact, sharing personal items, or any other means of transmission. Vitiligo i...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.